EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Why Johnson & Johnson May Be the Closest Thing Investors Can Find to a Bulletproof Dividend Stock - AOL
Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story
Johnson & Johnson (JNJ) Jury Rules in Favor of Company in Talc Lawsuit
Vestcor Inc Boosts Stock Position in Johnson & Johnson $JNJ
102,246 Shares in Johnson & Johnson $JNJ Bought by PBU The Pension Fund of Early Childhood & Youth Educators - Zolmax
111 Capital Makes New $1.74 Million Investment in Johnson & Johnson $JNJ
Arsenal Capital Advisors LLC Takes Position in Johnson & Johnson $JNJ
111 Capital Purchases Shares of 8,416 Johnson & Johnson $JNJ - Stock Observer
Johnson & Johnson beats lawsuit alleging that talc caused 3 women's cancer | The Straits Times
PBU The Pension Fund of Early Childhood & Youth Educators Buys New Position in Johnson & Johnson $JNJ - Daily Political
J&J beats lawsuit alleging that talc caused three women's cancer
Johnson & Johnson (NYSE:JNJ) Stock Price Up 2% - Still a Buy? - Zolmax
Johnson & Johnson (NYSE:JNJ) Shares Up 2% - Still a Buy?
Erste Group downgrades Deutsche Telekom (0MPH) to a Hold
Johnson & Johnson (JNJ) Gets a Buy from Guggenheim
Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations
Is It Time To Reassess Johnson & Johnson (JNJ) After A 52% One-Year Surge? - Simply Wall St News
Johnson & Johnson $JNJ Shares Sold by J.W. Cole Advisors Inc. - Zolmax
Dividend Aristocrats on Sale: 5 Decades-Long Raisers Trading Below Target
Total Wealth Planning & Management Inc. Takes $1.03 Million Position in Johnson & Johnson $JNJ - Zolmax
4,997 Shares in Johnson & Johnson $JNJ Bought by Total Wealth Planning & Management Inc.
313,929 Shares in Johnson & Johnson $JNJ Acquired by Arrowpoint Investment Partners Singapore Pte. Ltd.
Daiwa Securities Group Inc. Grows Position in Johnson & Johnson $JNJ - Stock Observer
Prudential PLC Has $81.29 Million Stock Holdings in Johnson & Johnson $JNJ - Daily Political
Johnson & Johnson $JNJ Shares Purchased by Deseret Mutual Benefit Administrators - Stock Observer
Vise Technologies Inc. Has $20.93 Million Stock Holdings in Johnson & Johnson $JNJ - Daily Political
Prestige Wealth Management Group LLC Has $7.04 Million Position in Johnson & Johnson $JNJ - Daily Political
Johnson & Johnson (NYSE:JNJ) Trading 2.3% Higher - Time to Buy?
JNJ: Future Drug Cycle Momentum Is Expected To Drive Returns
Jim Cramer's 5 Stock Calls, Including Alphabet and Eli Lilly, and Possible Opportunities
Top Healthcare Stocks To Add to Your Watchlist - June 4th - Zolmax
This Dividend King Is the Safest Dow Stock to Buy and Hold for 20 Years
Johnson And Johnson Autoimmune Trial Data And What It Means For JNJ
TD Asset Management Inc Increases Stock Holdings in Johnson & Johnson $JNJ
WCG Wealth Advisors LLC Acquires 22,434 Shares of Johnson & Johnson $JNJ
Greenspring Advisors LLC Purchases Shares of 7,353 Johnson & Johnson $JNJ
Johnson & Johnson $JNJ Position Boosted by Cibc World Market Inc.
Platform Wealth Management LLC Takes Position in Johnson & Johnson $JNJ - Stock Observer
Greenspring Advisors LLC Makes New Investment in Johnson & Johnson $JNJ - Stock Observer
First-in-India: Johnson & Johnson Receives Approval for VARIPULSE™ Platform, Advancing Atrial Fibrillation Treatment | Hindustan Times
Cibc World Market Inc. Acquires 70,817 Shares of Johnson & Johnson $JNJ - Stock Observer
Paul Hastings Settles With J&J Unit in Bankruptcy Fee Dispute
Mawer Investment Management Ltd. Acquires 14,220 Shares of Johnson & Johnson $JNJ - Zolmax
Johnson & Johnson (JNJ) Reports Positive Results for Lupus Treatment Nipocalimab
Johnson & Johnson (JNJ) Reveals Promising Data for Sjogren's Disease Treatment
Kesler Norman & Wride LLC Sells 38,128 Shares of Johnson & Johnson $JNJ
One Capital Management LLC Sells 33,786 Shares of Johnson & Johnson $JNJ
First-in-India: Johnson & Johnson Receives Approval for VARIPULSE™ Platform, Advancing Atrial Fibrillation Treatment
Johnson & Johnson (JNJ) Stock Rises on Positive Nipocalimab Lupus Trial Data
Johnson & Johnson $JNJ Shares Purchased by CIBC Asset Management Inc
Bank of New York Mellon Corp Cuts Stake in Johnson & Johnson $JNJ
Johnson & Johnson (JNJ) Reports Positive Phase 2 Results for Lupus Treatment
JNJ's Nipocalimab Meets Primary Goal In Phase 2 JASMINE Trial Of Systemic Lupus Erythematosus
Johnson & Johnson $JNJ Shares Sold by Westpac Banking Corp - Daily Political
A Look At Johnson & Johnson (JNJ) Valuation After Recent Share Price Weakness - Simply Wall St News
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study | Morningstar
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease | Morningstar
Top Healthcare Stocks To Watch Now - June 2nd - Daily Political
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic - AOL
Vantus Wealth LLC Makes New $995,000 Investment in Johnson & Johnson $JNJ
Natixis Advisors LLC Grows Stake in Johnson & Johnson $JNJ
Pincus Capital Management LP Invests $1.60 Million in Johnson & Johnson $JNJ
Johnson & Johnson $JNJ Position Raised by BNP Paribas
Citrate-functionalized manganese oxide nanoparticles in neonates ≥35 weeks gestation at risk of acute bilirubin encephalopathy: a phase 1 observational trial
Medical Stocks To Follow Today - June 1st - Stock Observer
JNJ DCF Analysis: Intrinsic Value $122 vs Price $225
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
Easterly Investment Partners LLC Lowers Holdings in Johnson & Johnson $JNJ
Is It Too Late To Consider Johnson & Johnson (JNJ) After Its 48% One-Year Surge?
Sage Investment Advisers LLC Purchases New Stake in Johnson & Johnson $JNJ - Daily Political
Is Johnson & Johnson (JNJ) One of the Best Dividend Paying Stocks to Buy Right Now?
Johnson & Johnson (JNJ) Reports Positive Phase 3 Study Results for Prostate Cancer Treatment
J&J's Erleada: Game-Changer in Prostate Cancer Treatment, ETPharma
How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier
Johnson & Johnson (JNJ) Reports Promising Trial Results for Amivantamab in Cancer Treatment
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivot
J&J therapy shows strong survival benefit in prostate cancer patients
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm | Morningstar
Johnson & Johnson $JNJ Shares Sold by Mitchell Capital Management Co. - Zolmax
Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study - The Economic Times
Top Healthcare Stocks To Consider - May 31st - Daily Political
Welch & Forbes LLC Lowers Holdings in Johnson & Johnson $JNJ
Essex Financial Services Inc. Buys 2,492 Shares of Johnson & Johnson $JNJ - Stock Observer
Nomura Asset Management Co. Ltd. Has $299.45 Million Stake in Johnson & Johnson $JNJ - Daily Political
Founders Financial Securities LLC Increases Stock Holdings in Johnson & Johnson $JNJ - Daily Political
Top Medical Stocks To Follow Today - May 30th - Stock Observer
How to Recession-Proof Your Retirement Income Before Summer 2026
JnJ News
US Monetary Policy Pivot: Non-Farm Payrolls, Inflation Fears, and Potential Rate Hikes
Netanyahu-Trump Rift Exposed: Ceasefire Talks Put Israeli Election Stakes in Jeopardy
US May Jobs Report: A Critical Indicator for the Fed's Interest Rate Path
Latest news
Show moreMarket Pulse: Dollar Rises, Gold Dips Post-US Jobs Data; Geopolitical Tensions Simmer
US May Jobs Report Signals Slowing Growth: A Deep Dive into Market Indicators
Hormuz Strait Oil Tanker Activity Shifts: Increased Secrecy and Market Fragmentation
US May Jobs Report Exceeds Expectations, Bolstering Economic Resilience and Shifting Fed Rate Outlook
